Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab + Atezolizumab + Chemo in TNBC
NCT04584112Phase 1Completed
- Sponsor
- Roche
- Start
- Sep 2020
- Primary completion
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 8
01
Overview
Phase 1, randomised, open-label trial of tiragolumab in triple-negative breast cancer (TNBC) (3 cohorts), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events up to 21 months and Confirmed Objective Response Rate up to 21 months. Started Sep 2020; status: completed.
02
Drugs
tiragolumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04584112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04584112.